Part of interview with Rolf Stahel chairman of NIMThe flotation...

Part of interview with Rolf Stahel chairman of NIM

The flotation this week of Norwood Immunology has finally got Mr Stahel out of the house. It is one of two biotech companies that he has joined as non-executive chairman, with a brief to pass on his experience of building Shire Pharmaceuticals from humble beginnings into a FTSE 100 stalwart worth almost £6bn at its peak in 2001.

Norwood, which promises a treatment to "reboot" the body's immune system and help fight cancer, raised £6m and began trading on AIM on